Jesse Schwartz - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Jesse Schwartz's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Jesse Schwartz
Verified
Contributor, Tech Transfer Central
Beats
Everything else.
Content
By Jesse Schwartz| Tech Transfer Central@ Start-up from U of Melbourne and Monash U advances novel approach to treating IBD By Jesse Schwartz | April 24th, 2024 A start-up jointly formed by the University of Melbourne and Monash University aims to commercialize a novel cell therapy approach for the treatment of Inflammatory Bowel Disease (IBD).
Weill Cornell Medicine and Lexeo Therapeutics sign license agreement to accelerate FA cardiomyopathy gene therapy
By Jesse Schwartz| Tech Transfer Central@ Weill Cornell Medicine and Lexeo Therapeutics sign license agreement to accelerate FA cardiomyopathy gene therapy By Jesse Schwartz | April 24th, 2024 Weill Cornell Medicine and clinical stage genetic medicine company Lexeo Therapeutics have signed an in-license agreement to accelerate the development of a gene therapy targeting Friedreich ataxia (FA) cardiomyopathy.
By Jesse Schwartz| Tech Transfer Central@ Start-up from U of Melbourne and Monash U advances novel approach to treating IBD By Jesse Schwartz | April 24th, 2024 A start-up jointly formed by the University of Melbourne and Monash University aims to commercialize a novel cell therapy approach for the treatment of Inflammatory Bowel Disease (IBD).
Company Info
Tech Transfer Central